Pfizer has announced that $130 million is being invested in two of its Irish manufacturing sites. $100 million is being invested in the Grange Castle site in Dublin and $30 million is being invested in the Ringaskiddy site in Cork.

The investments, which are supported by the Department of Jobs, Enterprise and Innovation through IDA Ireland, will enable the sites to expand their capacity and begin producing more advanced, complex therapies to deal with some of the most devastating and difficult to cure diseases.

Welcoming the announcement Minister for Jobs, Enterprise and Innovation, Richard Bruton said pharmaceuticals and life sciences generally is a hugely important sector for the Irish economy and the Government’s Action Plan for Jobs includes a series of measures to sustain and grow this sector.

Barry O’Leary, IDA CEO said the Ringaskiddy site was Pfizer’s first manufacturing facility in Ireland almost 45 years ago.

“Since Pfizer first set up in Ireland in the 1970s, it has invested more than $7 billion in developing the skills, scale and capability necessary to manufacture some of its leading medicines for global export from Ireland.’’

Ringaskiddy investment:

The $30 million investment in Ringaskiddy is to develop specialist new capability to manufacture some of Pfizer’s newest medicines in cancer and other future pipeline medicines. This investment ensures the Ringaskiddy site will be in a position to be considered for on-going development work on new products, not just for commercial launch, but also for clinical products.